1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
-
Mark
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer : Results from the Prospective, International, Observational Prostate Cancer Registry
(
- Contribution to journal › Article
- 2020
-
Mark
Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease : Semi-ecologic, Nationwide, Population-based Study
(
- Contribution to journal › Article
- 2013
-
Mark
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
(
- Contribution to journal › Scientific review
- 2012
-
Mark
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
(
- Contribution to journal › Article
- 2011
-
Mark
Psychiatric treatment in men with prostate cancer - Results from a Nation-wide, population-based cohort study from PCBaSe Sweden
(
- Contribution to journal › Article
- 2006
-
Mark
CYSTATIN C AND NEUROENDOCRINE DIFFERENTIATION IN THE MALE REPRODUCTIVE SYSTEM AND IN PROSTATE CANCER
2006)(
- Thesis › Doctoral thesis (compilation)